These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27885753)

  • 1. Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    McDonald SA; Innes HA; Aspinall E; Hayes PC; Alavi M; Valerio H; Goldberg DJ; Hutchinson SJ
    J Viral Hepat; 2017 Apr; 24(4):295-303. PubMed ID: 27885753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
    McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ
    J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis.
    McDonald SA; Innes HA; Aspinall EJ; Hayes PC; Alavi M; Valerio H; Goldberg DJ; Hutchinson SJ
    Liver Int; 2018 Aug; 38(8):1402-1410. PubMed ID: 29288595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
    McDonald SA; Barclay ST; Innes HA; Fraser A; Hayes PC; Bathgate A; Dillon JF; Went A; Goldberg DJ; Hutchinson SJ
    J Viral Hepat; 2021 Sep; 28(9):1246-1255. PubMed ID: 34002914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Hutchinson SJ; Valerio H; McDonald SA; Yeung A; Pollock K; Smith S; Barclay S; Dillon JF; Fox R; Bramley P; Fraser A; Kennedy N; Gunson RN; Templeton K; Innes H; McLeod A; Weir A; Hayes PC; Goldberg D
    Gut; 2020 Dec; 69(12):2223-2231. PubMed ID: 32217640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
    Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
    BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Flemming JA; Kim WR; Brosgart CL; Terrault NA
    Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage study.
    McDonald SA; Hutchinson SJ; Bird SM; Mills PR; Robertson C; Dillon JF; Williams T; Goldberg DJ
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):49-57. PubMed ID: 19773667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversion of disease manifestations after HCV eradication.
    van der Meer AJ; Berenguer M
    J Hepatol; 2016 Oct; 65(1 Suppl):S95-S108. PubMed ID: 27641991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
    Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
    J Hepatol; 2018 Mar; 68(3):393-401. PubMed ID: 29107152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
    van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease outcomes in a cohort of women in Ireland infected by hepatitis C-contaminated anti-D immunoglobulin during 1970s.
    Garvey P; Murphy N; Flanagan P; Brennan A; Courtney G; Crosbie O; Crowe J; Hegarty J; Lee J; McIver M; McNulty C; Murray F; Nolan N; O'Farrelly C; Stewart S; Tait M; Norris S; Thornton L
    J Hepatol; 2017 Dec; 67(6):1140-1147. PubMed ID: 28843656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C.
    Ogawa E; Chien N; Kam L; Yeo YH; Ji F; Huang DQ; Cheung R; Nguyen MH
    JAMA Intern Med; 2023 Feb; 183(2):97-105. PubMed ID: 36508196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis.
    Iacobellis A; Perri F; Valvano MR; Caruso N; Niro GA; Andriulli A
    Clin Gastroenterol Hepatol; 2011 Mar; 9(3):249-53. PubMed ID: 21092761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.